Isabel Virella‐Lowell

542 total citations
17 papers, 359 citations indexed

About

Isabel Virella‐Lowell is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, Isabel Virella‐Lowell has authored 17 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Isabel Virella‐Lowell's work include Cystic Fibrosis Research Advances (8 papers), Virus-based gene therapy research (3 papers) and Respiratory viral infections research (3 papers). Isabel Virella‐Lowell is often cited by papers focused on Cystic Fibrosis Research Advances (8 papers), Virus-based gene therapy research (3 papers) and Respiratory viral infections research (3 papers). Isabel Virella‐Lowell collaborates with scholars based in United States, France and Switzerland. Isabel Virella‐Lowell's co-authors include Terence R. Flotte, Kye Chesnut, Mark Brantly, Hong Yu, Maria F. Lopes‐Virella, Thomas W. Ferkol, Gabriel Virella, Bill X. Wu, Yusuf A. Hannun and Youssef H. Zeidan and has published in prestigious journals such as The Journal of Immunology, Molecular Therapy and American Journal of Respiratory Cell and Molecular Biology.

In The Last Decade

Isabel Virella‐Lowell

16 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabel Virella‐Lowell United States 10 154 139 102 79 60 17 359
L. McIlreavey United Kingdom 9 234 1.5× 319 2.3× 37 0.4× 59 0.7× 25 0.4× 12 527
Bonggoo Park United States 7 74 0.5× 102 0.7× 18 0.2× 49 0.6× 104 1.7× 7 394
David Henke United States 9 141 0.9× 177 1.3× 33 0.3× 240 3.0× 18 0.3× 15 506
Xuyang Xia China 10 39 0.3× 175 1.3× 41 0.4× 39 0.5× 46 0.8× 17 331
Fuminari Sonoda Japan 9 174 1.1× 91 0.7× 16 0.2× 98 1.2× 154 2.6× 13 427
Rhonda Henley‐Smith United Kingdom 7 32 0.2× 85 0.6× 34 0.3× 71 0.9× 61 1.0× 8 287
Sina Marsilio United States 12 196 1.3× 183 1.3× 39 0.4× 41 0.5× 38 0.6× 28 397
Stefan Löseke Germany 7 123 0.8× 77 0.6× 13 0.1× 91 1.2× 74 1.2× 12 318
Ashley R. Carpenter United States 10 55 0.4× 191 1.4× 28 0.3× 109 1.4× 59 1.0× 20 435
E.I. Arafa United States 9 71 0.5× 107 0.8× 16 0.2× 85 1.1× 211 3.5× 14 356

Countries citing papers authored by Isabel Virella‐Lowell

Since Specialization
Citations

This map shows the geographic impact of Isabel Virella‐Lowell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Virella‐Lowell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Virella‐Lowell more than expected).

Fields of papers citing papers by Isabel Virella‐Lowell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Virella‐Lowell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Virella‐Lowell. The network helps show where Isabel Virella‐Lowell may publish in the future.

Co-authorship network of co-authors of Isabel Virella‐Lowell

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Virella‐Lowell. A scholar is included among the top collaborators of Isabel Virella‐Lowell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Virella‐Lowell. Isabel Virella‐Lowell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Muhlebach, Marianne S., Thomas W. Shields, Kushal Shah, et al.. (2024). Assessing effectiveness of cleaning and disinfection of equipment and environmental surfaces in cystic fibrosis clinics using an ATP assay. Infection Control and Hospital Epidemiology. 45(10). 1213–1218.
2.
Donald, L., Margaret Rosenfeld, Lloyd Mancl, et al.. (2018). Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6–20 years: A pilot study. Journal of Cystic Fibrosis. 17(6). 747–759. 12 indexed citations
3.
Virella‐Lowell, Isabel, et al.. (2018). Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatric Pulmonology. 53(7). E21–E23. 7 indexed citations
4.
Sommerwerck, Urte, et al.. (2016). Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Current Medical Research and Opinion. 32(11). 1789–1795. 13 indexed citations
5.
Virella‐Lowell, Isabel, et al.. (2015). Quantitative Sinonasal Symptom Assessment in an Unselected Pediatric Population with Cystic Fibrosis. American Journal of Rhinology and Allergy. 29(5). 357–361. 15 indexed citations
6.
Yu, Hong, et al.. (2010). IL-10 delivery by AAV5 vector attenuates inflammation in mice with pseudomonas pneumonia. Gene Therapy. 17(5). 567–576. 27 indexed citations
7.
Yu, Hong, Youssef H. Zeidan, Bill X. Wu, et al.. (2009). Defective Acid Sphingomyelinase Pathway with Pseudomonas aeruginosa Infection in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 41(3). 367–375. 50 indexed citations
8.
Ghegan, Mark D., Sarah K. Wise, David R. White, et al.. (2008). Cost-effective airway cultures in the cystic fibrosis patient. American Journal of Otolaryngology. 30(3). 150–152. 5 indexed citations
9.
Yu, Hong, et al.. (2008). Oral instillation with surfactant phospholipid: a reliable alternative to intratracheal injection in mouse studies. Laboratory Animals. 42(3). 294–304. 11 indexed citations
10.
Schaffer, Frederick M., Isabel Virella‐Lowell, Richard A. Gatti, & David Gossage. (2007). Ataxia-Telangiectasia, Associated with a Rare 1339C>T ATM mutation, presenting in infancy with Pneumocystis carinii pneumonia, and an elevated serum IgM.. The Journal of Immunology. 178. 2 indexed citations
11.
Schaffer, Frederick M., Isabel Virella‐Lowell, Richard A. Gatti, & David Gossage. (2007). Ataxia-Telangiectasia, Associated with a Rare 1339C>T ATM mutation, presenting in infancy with Pneumocystis carinii pneumonia, and an elevated serum IgM. (35.11). The Journal of Immunology. 178(1_Supplement). S3–S3. 1 indexed citations
12.
Flume, Patrick A., et al.. (2005). Emergency Preparedness for the Chronically Ill. AJN American Journal of Nursing. 105(3). 68–72. 7 indexed citations
13.
Virella‐Lowell, Isabel, Kevin D. Foust, Scott Loiler, et al.. (2005). Enhancing rAAV vector expression in the lung. The Journal of Gene Medicine. 7(7). 842–850. 53 indexed citations
14.
Virella‐Lowell, Isabel, et al.. (2004). Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line. Molecular Therapy. 10(3). 562–573. 43 indexed citations
15.
Flotte, Terence R., Isabel Virella‐Lowell, & Kye Chesnut. (2003). Adeno-Associated Viral Vectors for CF Gene Therapy. Humana Press eBooks. 70. 599–608. 2 indexed citations
16.
Virella‐Lowell, Isabel, et al.. (2000). Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Therapy. 7(20). 1783–1789. 73 indexed citations
17.
Virella, Gabriel, et al.. (1997). Anti-Modified LDL Antibodies and LDL-Containing Immune Complexes in IDDM Patients and Healthy Controls. Clinical Immunology and Immunopathology. 85(1). 73–82. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. McIlreavey Breakdown of academic impact, for papers by Bonggoo Park Breakdown of academic impact, for papers by David Henke Breakdown of academic impact, for papers by Xuyang Xia Breakdown of academic impact, for papers by Fuminari Sonoda Breakdown of academic impact, for papers by Rhonda Henley‐Smith Breakdown of academic impact, for papers by Sina Marsilio Breakdown of academic impact, for papers by Stefan Löseke Breakdown of academic impact, for papers by Ashley R. Carpenter Breakdown of academic impact, for papers by E.I. Arafa
Rankless by CCL
2026